Table 1 Outcomes of clinical trials using mosunetuzumab in indolent lymphomas

FL, ≥ 3 line

M

I.V. 8–17 cycles 1/2/60/30

80%/60%

24-month PFS, 48% (36–60)

24-month OS, 87% (80–94)

mDOR, not reached

CRS: 44%, 2% ≥ grade 3

ICANS: 4.4% (no ≥ grade 3)

1, 2

iNHL

 > 1 line

M

Subq 8–17 cycles

G1: 5/15/45

G2: 5/45/45

G3: 5/90/45

82%/55%

mDOR, not reached

*CRS: 28%, 0% ≥ grade 3 *ICANS: 3.4% (3 grade 1)

4

FL

M + len

M: I.V. 12 cycles

Len: 11 cycles (C2-12)

90%/72%

n/a

CRS: 28%, 0% ≥ grade 3

ICANS: n/a

9, 10